ABSTRACT
BACKGROUND: After thyroidectomy some patients experience a chronic fatigue syndrome called asthenia. The purpose of this study was to determine the post-operative health related quality of life (HRQOL) and risk of asthenia in patients undergoing thyroidectomy. METHODS: A single institution prospective observational cohort study of adults undergoing thyroidectomy from September 2016 to July 2019 with four HRQOL surveys: preoperative baseline, 2 wk-, 6 mo- and 12 mo-postoperatively. Patients were surveyed using the Short Form 36 version 2 and Brief Fatigue Inventory. Asthenia was defined as Brief Fatigue Inventory > 60 at 12 mo. HRQOL was compared between patients undergoing thyroid lobectomy (TL) or total thyroidectomy (TT) with benign (-B) or malignant (-Ca) final pathology. RESULTS: A total of 182 patients were included: 67 (37%) with TL-B, 32 (17%) with TL-Ca, 40 (22%) with TT-B, and 43 (24%) with TT-Ca. The incidence of asthenia was 42% for TT and 4% for TL. In the TL-B group, 2 patients (3%) developed asthenia, compared with 2 patients (6.25%) in the TL-Ca group, 14 patients (35%) in the TT-B group, and 21 (48.8%) in the TT-Ca group (P = 0.0001). The odds ratio of asthenia for TT compared to TL was 10.4 (95% CI 3.86-28.16) and for patients with malignancy compared to benign disease was 2.05 (95% CI 1.17-3.61). CONCLUSIONS: Patients undergoing TT have a higher risk of developing asthenia than those undergoing TL, particularly if the final pathology shows malignancy.
Subject(s)
Asthenia/epidemiology , Patient Reported Outcome Measures , Postoperative Complications/epidemiology , Quality of Life , Thyroidectomy/adverse effects , Adult , Aged , Asthenia/etiology , Asthenia/psychology , Female , Humans , Incidence , Male , Middle Aged , Postoperative Complications/etiology , Postoperative Complications/psychology , Prospective Studies , Thyroid Gland/pathology , Thyroid Gland/surgery , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery , Thyroidectomy/methodsABSTRACT
AIM: To assess the formation of positive personality phenomena in patients with mild cognitive impairment and asthenic syndrome during the treatment with recognan (citicoline). MATERIAL AND METHODS: Thirty-eight patients (17 men and 21 women), aged 18 to 45 years (mean age 27.8±12.1 years), with asthenic syndrome with mild cognitive impairment (ICD-10 F06.7) were examined. Patients were divided into two groups: 20 people in the main group and 18 people in the comparison group. The main group received recognan (orally, in solution, 100 mg in 1 ml) for 30 days, the daily dosage of the drug was 0.5 g (5 ml solution). The comparison group did not receive any medications. Adapted methods of positive personality psychology were used: the Fordyce Emotions Questionnaire, the Subjective Happiness Scale (SHS), the Adult Hope Scale (AHS), the Satisfaction with Life Scale (SWLS), M. Atkinson's Scale of Emotional Maturity, the projective technique 'Map of experiences'. The follow-up period was 30 days. All subjects were examined three times (at baseline, 15 and 30 days after treatment). RESULTS AND CONCLUSION: After a month of treatment with recognan, there was an improvement of positive personality traits and a significant decrease in negative experiences, indicating the positive impact of the drug on the formation of positive personality manifestations and compensation for emotional disorders in patients with mild cognitive impairment and asthenic syndrome.
Subject(s)
Asthenia/complications , Asthenia/drug therapy , Cognitive Dysfunction/complications , Cognitive Dysfunction/drug therapy , Cytidine Diphosphate Choline/therapeutic use , Personality Disorders/complications , Personality Disorders/drug therapy , Personality/drug effects , Adolescent , Adult , Asthenia/psychology , Cognitive Dysfunction/psychology , Cytidine Diphosphate Choline/pharmacology , Female , Humans , Male , Middle Aged , Personality Disorders/psychology , Young AdultABSTRACT
The features of clinical symptoms, neurotic disorders and the level of subjective control were studied in patients with fibromyalgia. The analysis of relationship between the level of subjective control and neurotic symptoms (asthenia, depression, anxiety, hypochondria) depending the severity of main clinical manifestations of the disease was carried out. It was found that high intensity of fatigue, muscle pain, stiffness, insomnia, and an increase in the number of diagnostic tender points contribute to the formation of inverse correlation between the level of subjective control and neurotic disturbances. Thus, the increase of the externality of the level of subjective control allows indicating to the formation of patients' passivity in relation to their disease, the lack of adherence to prescribed course of treatment (low compliance). Although drug therapy is the main component of complex treatment of fibromyalgia patients, patients require significantly more - successful treatment requires active involvement of patients in the therapy process, as well as changes in their attitudes and lifestyle, which can be achieved by training in so-called "schools" for patients, use of psychotherapeutic methods.
Subject(s)
Anxiety/psychology , Asthenia/psychology , Depression/psychology , Fatigue Syndrome, Chronic/psychology , Fibromyalgia/psychology , Hypochondriasis/psychology , Adult , Analgesics/therapeutic use , Anxiety/diagnosis , Anxiety/physiopathology , Anxiety/therapy , Asthenia/diagnosis , Asthenia/physiopathology , Asthenia/therapy , Autogenic Training/methods , Cohort Studies , Depression/diagnosis , Depression/physiopathology , Depression/therapy , Fatigue Syndrome, Chronic/diagnosis , Fatigue Syndrome, Chronic/physiopathology , Fatigue Syndrome, Chronic/therapy , Female , Fibromyalgia/diagnosis , Fibromyalgia/physiopathology , Fibromyalgia/therapy , Humans , Hypnosis/methods , Hypochondriasis/diagnosis , Hypochondriasis/physiopathology , Hypochondriasis/therapy , Middle Aged , Research Design , Severity of Illness IndexABSTRACT
We herein present a case of a 20-year-old woman who suffered from type I diabetes mellitus and died from a diabetic ketoacidosis in a context of addiction to hyperglycemia. Diabetic ketoacidosis is a lethal complication of insulin-dependent diabetes mellitus, which can result from insulin therapy stoppage. This can occur voluntarily with suicidal intent or involuntarily due to treatment inaccessibility, forgotten injections, or material deficiency. A new possibility is investigated in our case study: hyperglycemia addiction. The patient was treated by insulin glargine and insulin aspartate. She regularly stopped insulin glargine injections seeking the asthenia sensation produced by hyperglycemia, keeping the insulin aspartate injections to treat the disabling symptom related to hyperketonemia.
Subject(s)
Asthenia/psychology , Behavior, Addictive , Diabetic Ketoacidosis/etiology , Hyperglycemia/psychology , Asthenia/etiology , Depression/psychology , Diabetes Mellitus, Type 1/drug therapy , Female , Humans , Hyperglycemia/etiology , Hypoglycemic Agents/administration & dosage , Insulin Aspart/administration & dosage , Insulin Glargine/administration & dosage , Medication Adherence , Young AdultABSTRACT
This study explores factors in childhood and adulthood that affect adult trait Neuroticism in a large, nationally representative sample. 5785 participants provided information on family social background measured at birth; Intelligence assessed at 11 years; Behavioural problems measured at 11 years; Malaise assessed at 23 years; Educational qualifications obtained at 33 years; Occupational levels at 42 years, and personality trait Neuroticism measured at 50 years. Structural equation modelling showed that sex, childhood Behavioural Problems, childhood Intelligence, Malaise in early adulthood, and Occupation were all significant and independent predictors of adult trait Neuroticism. Parental social status was significantly and negatively associated with Malaise at age 23, but was not a significant predictor of trait Neuroticism at age 50 years. Education predicted Neuroticism mainly through occupation. The strongest predictor of trait Neuroticism at 50 years was Malaise measured at 23 years, with a corrected correlation of r = .42 over the 27 year period. The results suggest some underlying biological/genetic mechanism.
Subject(s)
Neuroticism , Personality Disorders/psychology , Adolescent , Adult , Asthenia/psychology , Child , Fatigue/psychology , Female , Humans , Intelligence , Male , Middle Aged , Parents , Risk Factors , Social Environment , Young AdultABSTRACT
OBJECTIVE: To analyze the prevalence, methods of diagnosis and treatment of psychogenic dizziness in patients with arterial hypertension and evaluate the efficacy of treatment with noophen and betahistin. MATERIAL AND METHODS: Fifty-eight patients were studied. Patients of the main group received noophen and patients of the comparison group were treated with betahistin. Treatment efficacy was assessed on days 1 and 60 by the scores on VAS, HARS, MFI-20 scales. RESULTS AND CONCLUSION: The prevalence of psychogenic dizziness in patients with arterial hypertension was 47%. Noophen in dose 500 mg/day significantly (p<0.001) reduced the severity of dizziness, anxiety, asthenia, and headache compared to baseline and to the efficacy of betahistin as well. The drug showed good tolerability.
Subject(s)
Betahistine/therapeutic use , Dizziness/drug therapy , Dizziness/etiology , Hypertension/complications , gamma-Aminobutyric Acid/analogs & derivatives , Aged , Anxiety/drug therapy , Anxiety/psychology , Asthenia/drug therapy , Asthenia/psychology , Dizziness/diagnosis , Female , Humans , Hypertension/psychology , Male , Treatment Outcome , gamma-Aminobutyric Acid/therapeutic useABSTRACT
AIM: To investigate the level of anxiety and the severity of asthenic state in patients with staghorn nephrolithiasis treated by of minimally invasive therapies - percutaneous nephrolithotripsy (PNLT) and retrograde nephrolithotripsy (RNLT). PATIENTS AND METHODS: This study analyzed the psychological state of 150 patients with staghorn nephrolithiasis aged 25 to 75 years before and after PNLT and RNLT. Testing was performed at baseline, at 5-7 day of hospital stay (average time of preparing for surgery) and after treatment with the use of various questionnaires: Anxiety Scale, Asthenic conditions scale and Pain questionnaire. RESULTS: The follow-up findings shower positive changes, including reduction in the level of anxiety and severity of asthenia in patients of different age groups. The decrease in anxiety level and severity of fatigue was associated with decreased rates of neuropathic component of pain. CONCLUSION: The psychological state of patients with staghorn nephrolithiasis depends on the characteristics of minimally invasive methods of treatment and requires attending physicians and medical personnel to take into consideration the mental and emotional state of patients.
Subject(s)
Nephrolithiasis/psychology , Adult , Aged , Anxiety/psychology , Asthenia/psychology , Humans , Lithotripsy/methods , Middle Aged , Nephrolithiasis/therapy , Surveys and QuestionnairesABSTRACT
OBJECTIVE: Our aim was to assess effect of antiasthenic drug adamantilbromphenylamine on the immune system and symptoms of asthenia in patients with non-psychotic mental disorders and to reveal possible criteria for prediction of treatment efficiency. METHODS: Uncontrolled study with interrupted time series was carried out. According to efficiency of treatment patients were divided into two groups (group 1 (n=21)--very much improved and much improved; group 2 (n=9)--minimally improved). Adamantilbromphenylamine was administered to patients as a monotherapy 100 mg a day for 28 days. Examination was conducted before and after therapy. Severity of asthenic symptoms according to MFI-20 scale was identified; cellular and humoral immunity parameters, mitogen-induced production of interleukins (IL) 1ß and IL 4 by immunocompetent cells of patients were assessed. RESULTS: 30 patients with non-psychotic mental disorders with predominance of asthenic symptomatology in clinical picture of the disease were examined. Before therapy every proband had over 60 points across 5 items of MFI-20 scale. As compared with control decrease of number of lymphocytes of CD3+-, HLA-DR+, CD16+-phenotypes; increase in the ratio of CD4+/CD8+; concentration of serum IgM; phagocytic activity of neutrophils were revealed. In the end of therapy in group 1, sum total of points of asthenia decreased up to 26(23-37) (p<0.001); in group 2--up to 57(47-61). Only in group 1 positive dynamic of immune parameters was revealed. It was shown that baseline level of proinflammatory cytokine IL 1ß in group with apparent therapeutic effect of the drug was reliably lower, than in group with minimal improvement (p=0.005). These differences remained also after course of therapy (p=0.042). CONCLUSION: Interrelationship of clinical-immunological effect of adamantilbromphenylamine has been revealed; intensity of production of IL 1ß may be considered as a criterion of prognosis of efficiency of treatment with adamantilbromphenylamine in patients with non-psychotic mental disorders.
Subject(s)
Antipsychotic Agents/administration & dosage , Asthenia/drug therapy , Immunity, Cellular , Mental Disorders/drug therapy , Adult , Asthenia/immunology , Asthenia/psychology , Dose-Response Relationship, Drug , Female , Humans , Male , Mental Disorders/immunology , Mental Disorders/psychology , Middle Aged , Prognosis , Young AdultABSTRACT
There is clinical evidence that post-total thyroidectomy (TT) patients can present persistent asthenia. The aim of this study was to evaluate the prevalence of asthenia symptoms in such patients, assess whether a chronic asthenia syndrome could be caused by TT or become evident after it. An observational study was carried out comparing two groups of 100 patients each, all with homogeneous characteristics. Group A was treated with total lobectomy (TL), Group B with TT. All patients presented normal thyroid hormone levels. The patients were interviewed in order to identify the ones affected by post-operative asthenia persisting for at least six months, with reduced ability to perform physical and mental work, not showing improvement with rest. The severity of the symptoms has been measured by means of the brief fatigue inventory (BFI). Statistical analysis was performed to evaluate statistically significative differences between groups and prognostic factors in TT group. The incidence of post-operative asthenia was 0 % after TL and 25 % after TT, with the operation being the only significant variable. Asthenia is well known as symptom of post-thyroidectomy, but it has not been adequately investigated as consequence of surgery. We demonstrated that the complete removal of the thyroid gland could determine chronic post-thyroidectomy asthenia, although with intensity limited to low/moderate. Post-thyroidectomy asthenia is a relevant sequela interfering with quality of life of at least 25 % of patients operated, suggesting the need to identify its real causes and limit the indication to TT only when strictly required.
Subject(s)
Asthenia/etiology , Fatigue/etiology , Thyroidectomy/adverse effects , Adult , Aged , Asthenia/diagnosis , Asthenia/psychology , Deception , Fatigue/diagnosis , Fatigue/psychology , Female , Humans , Male , Middle Aged , Quality of Life , Severity of Illness Index , Thyroidectomy/methodsABSTRACT
The present observational study addressed effects of cytoflavine on symptoms of asthenia and emotional and autonomic regulation in patients with organic emotional-labile (asthenic) disorder (F06.6). Fifty one females and 49 males (mean age 36.8±11.0 years) were included into the study during their in-patient treatment in Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department. All patients received standard antidepressant and vascular therapy, were consulted by psychologists or psychotherapists, visited physiotherapeutic procedures, massage and medical physical training. In addition, 50 patients received cytoflavin two tablets twice per day. At the psychiatric re-assessment before discharge both cytoflavin and control groups showed similar significant reduction of asthenia symptoms. At the same time, patients with cognitive deficits showed significantly larger improvement of cognitive functions after cytoflavin treatment in comparison with cognitively deficient patients after only standard therapy. Improvement of depressive symptoms was significantly larger in cytoflavin group in comparison with controls as well. These data are consistent with previous studies which showed cytoflavin to be effective as a treatment for patients with cognitive deficits and organic depression.
Subject(s)
Asthenia/drug therapy , Flavin Mononucleotide/therapeutic use , Inosine Diphosphate/therapeutic use , Neuroprotective Agents/therapeutic use , Niacinamide/therapeutic use , Succinates/therapeutic use , Adult , Asthenia/physiopathology , Asthenia/psychology , Autonomic Nervous System/drug effects , Drug Combinations , Emotions/drug effects , Female , Humans , Male , Middle Aged , Treatment OutcomeABSTRACT
There are presented the data of workers overstrain and fatigue conditions mechanisms based on physiological, psychological and ergonomic aspects of work processes in different types of activities (mental, visual-strained, physical). 15-year historical analysis, current state and prospects of labor physiology methods development are shown. Complex physiological and ergonomic investigations have allowed developing the measures of work ability raise and diseases prevention for workers various professions. Obtained results provided the basis of development of regulatory documents in area of human organism strain physiological norms, consequences of psycho-emotional stress and overstrain prevention taking into account working conditions class.
Subject(s)
Asthenia , Burnout, Professional , Fatigue , Occupational Diseases , Occupational Exposure , Occupations/classification , Asthenia/diagnosis , Asthenia/etiology , Asthenia/physiopathology , Asthenia/prevention & control , Asthenia/psychology , Burnout, Professional/diagnosis , Burnout, Professional/etiology , Burnout, Professional/physiopathology , Burnout, Professional/prevention & control , Burnout, Professional/psychology , Fatigue/diagnosis , Fatigue/etiology , Fatigue/physiopathology , Fatigue/prevention & control , Fatigue/psychology , Forms and Records Control , Humans , Occupational Diseases/diagnosis , Occupational Diseases/physiopathology , Occupational Diseases/prevention & control , Occupational Diseases/psychology , Occupational Exposure/adverse effects , Occupational Exposure/classification , Occupational Health , Occupational Health Services/methods , Psychology, Industrial/methods , Task Performance and AnalysisABSTRACT
The authors present the results of a survey of 103 patients aged 25 to 45 years with burnout syndrom. The results showed that most patients with the syndrome of burnout have clinical manifestations of asthenia, varying degrees of severity. According to psychological and psychophysiological examination in this group of patients were found attention and memory dysfunction. This study evaluated the efficacy of memoplant in the treatment of this pathology. The high efficiency of memoplant (improvement in 69.7% of cases) was detected, confirmed by the data of the clinical, psychological and neuropsychological research.
Subject(s)
Asthenia/epidemiology , Burnout, Professional/epidemiology , Adult , Asthenia/diagnosis , Asthenia/physiopathology , Asthenia/psychology , Attention Deficit Disorder with Hyperactivity/epidemiology , Attention Deficit Disorder with Hyperactivity/physiopathology , Attention Deficit Disorder with Hyperactivity/psychology , Burnout, Professional/diagnosis , Burnout, Professional/physiopathology , Burnout, Professional/psychology , Female , Humans , Male , Memory Disorders/epidemiology , Memory Disorders/physiopathology , Memory Disorders/psychology , Middle Aged , Neuropsychological Tests , SyndromeABSTRACT
The objective of the present clinical and psychopathological study was to estimate the influence of high-intensity white and yellow phototherapy on the clinical condition of 41 and 18 patients respectively presenting with astheno-depressive syndrome. The control group was comprised of 42 patients who were treated by standard pharmacotherapy. Clinical observations of the patients were supplemented by the evaluation of their conditions and characteristics using the Symptom Checklist-90 questionnaire, the Bekhterev Depression Inventory, and the Beck Depression Inventory. The patients of the three groups were surveyed before and within 20 days after the initiation of the treatment. It was shown that white light phototherapy considerably reduced the severity of asthenia and depression. Yellow light phototherapy proved more efficacious in the patients with asthenia and somatovegetative dysfunctions.
Subject(s)
Asthenia/therapy , Color Therapy/methods , Depression/therapy , Neurotic Disorders/therapy , Adolescent , Adult , Aged , Asthenia/psychology , Depression/psychology , Female , Humans , Male , Middle Aged , Neurotic Disorders/psychologyABSTRACT
BACKGROUND: The objectives of this pilot study were to evaluate the safety and efficacy of the central nervous system stimulant methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel. PATIENTS AND METHODS: Patients with early breast cancer who presented asthenia >3 on the Visual Analogue Scale (VAS) after the first cycle of docetaxel-based chemotherapy were included. Patients received two additional cycles of chemotherapy, one with methylphenidate (10 mg bid) and the other without methylphenidate. Asthenia was evaluated using VAS and the Functional Assessment of Cancer Therapy-Fatigue (FACT-F) scale. Distress was assessed using the Hospital Anxiety and Depression Scale (HADS), and quality of life using FACT-F. RESULTS: Ten patients were included and evaluated for efficacy and safety. Overall, cycles with methylphenidate were better tolerated than those without methylphenidate in terms of asthenia (VAS, p = 0.004; FACT-F, p = 0.027) and quality of life (FACT-F, p = 0.047). No significant differences were observed in terms of distress (HADS, p = 0.297). Six (60%) patients continued with methylphenidate after study end. Main adverse events during study were palpitations and insomnia (30% of patients each). CONCLUSIONS: This pilot study suggests that methylphenidate may reduce asthenia and improve quality of life in breast cancer patients treated with docetaxel.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Asthenia/drug therapy , Breast Neoplasms/drug therapy , Central Nervous System Stimulants/therapeutic use , Methylphenidate/therapeutic use , Activities of Daily Living , Adult , Aged , Asthenia/chemically induced , Asthenia/diagnosis , Asthenia/psychology , Breast Neoplasms/pathology , Central Nervous System Stimulants/adverse effects , Cross-Over Studies , Docetaxel , Female , Humans , Methylphenidate/adverse effects , Middle Aged , Pilot Projects , Prospective Studies , Quality of Life , Severity of Illness Index , Spain , Surveys and Questionnaires , Taxoids/adverse effects , Time Factors , Treatment OutcomeABSTRACT
Self-evaluation of single-dose (15 mg) action and course treatment (30 mg daily) results were studied in patients with anxiety and asthenic disorders treated with the new anxiolytic afobazole. Also, relationships between self-evaluated parameters and personal features, clinician-rated therapeutic changes, and treatment effectiveness were analyzed. The study was conducted according to formalized protocol using standard scales and methods. Results suggest that higher self-rated tolerability and patient acceptability were associated with afobazole treatment in comparison to benzodiazepines. The results revealed relationships between self-evaluated single-dose effects of afobazole and other parameters, personal features, cognitive impairments severity, main drug effects, and overall treatment effectiveness.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Asthenia/drug therapy , Benzimidazoles/therapeutic use , Diagnostic Self Evaluation , Morpholines/therapeutic use , Adolescent , Adult , Anti-Anxiety Agents/administration & dosage , Anxiety/psychology , Asthenia/psychology , Benzimidazoles/administration & dosage , Cognition Disorders/etiology , Cognition Disorders/psychology , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Morpholines/administration & dosage , Neuropsychological Tests , Patient Compliance , Patient Satisfaction , Severity of Illness Index , Treatment Outcome , Young AdultABSTRACT
The author presents results of multicentre randomized studies of therapeutic efficiency of cytoflavin tablets in patients with chronic cerebral ischemia including asthenovegetative syndrome. Cytoflavin was shown to reduce clinical manifestations of asthenia, anxiety, depression, cognitive and emotional disorders and simultaneously improve quality of life. The efficiency of cytoflavin is confirmed by improved physical and psychic state of the patients, their enhanced social activity.
Subject(s)
Brain Ischemia/drug therapy , Flavin Mononucleotide/therapeutic use , Inosine Diphosphate/therapeutic use , Niacinamide/therapeutic use , Succinates/therapeutic use , Asthenia/drug therapy , Asthenia/psychology , Brain Ischemia/physiopathology , Brain Ischemia/psychology , Chronic Disease , Drug Combinations , Humans , Multicenter Studies as Topic , Neuropsychological Tests , Quality of Life , Randomized Controlled Trials as TopicABSTRACT
Based on the examination of 242 women, mean age 30,7+/-0,3 years, with hypertrophic form of autoimmune thyroiditis (Hashimoto disease) in the state of euthyreosis, we analyzed psychoendocrinological factors, responsible for immune reactions, taking into account the thyroid gland structure. We observed the strong correlations between the intensity of autoimmunity, morphological features, psychiatric and hormonal changes.
Subject(s)
Asthenia/etiology , Autoimmunity/physiology , Depression/etiology , Gonadal Steroid Hormones/blood , Psychometrics/methods , Reproduction , Thyroiditis, Autoimmune/complications , Adult , Asthenia/diagnosis , Asthenia/psychology , Autoantibodies/blood , Chronic Disease , Depression/diagnosis , Depression/psychology , Disease Progression , Female , Humans , Prognosis , Thyroiditis, Autoimmune/blood , Thyroiditis, Autoimmune/immunologyABSTRACT
AIMS: Individuals with asthma may be at increased risk of depression, but few studies have identified precursors to the onset of depression. The study goal was to identify risk factors for depression onset among a community-based sample of adults with asthma. METHODS: Data were obtained from three telephone interviews conducted at 2-yearly intervals on a longitudinal cohort of adults with asthma (n=439). The Center for Epidemiologic Studies Depression scale (CESD) was used to measure depressive symptoms. Multiple regression analyses tested associations of sociodemographic and health-related variables with depression prevalence (cross-sectional analyses) and incident depression (longitudinal analyses). RESULTS: 15% of subjects were classified as "depressed" (CESD> or =23) at each interview. Individuals depressed at baseline were more likely to drop out (OR=1.76 [95% CI 1.05, 2.96]). Low perceived control of asthma (measured with the Perceived Control of Asthma Questionnaire [PCAQ]) exhibited the most consistent association with depression. Lower PCAQ was cross-sectionally associated with depression (OR=0.51 per 0.5 SD difference in PCAQ [0.35, 0.75]). Onset of depression was noted in 38 individuals. Decrease in perceived control at follow-up was associated with depression onset (OR=7.47 [2.15, 26.01]). CONCLUSIONS: Low perceived control of asthma predicted depression onset among adults with asthma. This risk factor may respond to self-management education.